eXoZymes (EXOZ) Q2 2026 earnings summary

Executive summary

• Achieved a 10x productivity breakthrough in NCT manufacturing, improving process economics and commercial readiness, with a 67% higher yield per liter and over 80% reduction in reaction time.

• Advanced NCT commercialization by selecting manufacturing partners and building a scalable, asset-light production model.

• Secured $20M in non-dilutive capital from government grants, including a $2M NIH SBIR grant for cannabinoid analogs and a $3M NSF grant for cell-free systems.

• Refined strategy to focus on high-value nutraceuticals and pharmaceuticals, leveraging AI-enhanced biomanufacturing.

• Operates as a single reportable segment, managing all activities on a consolidated basis.

Financial highlights

• Cash and cash equivalents at June 30, 2026 were $5.65M, up from $3.04M at year-end 2025, primarily due to June 2026 equity offerings.

• Completed two financing events in June 2026, raising $6.59M gross proceeds through stock and warrant offerings.

• Operating expenses for H1 2026 were $5.34M, up 18.7% year-over-year; Q2 expenses were $2.95M, up from $2.55M in Q2 2025.

• Net loss for H1 2026 was $5.25M, a 24.5% increase year-over-year; Q2 net loss was $2.88M.

• Working capital improved to $4.55M as of June 30, 2026.

Outlook and guidance

• Sufficient liquidity to support operations and initiatives through end of 2026, though management notes substantial doubt about ability to continue as a going concern without additional funding.

• Expect to finalize NCT production partner and technology transfer package, and announce market launch partner by end of 2026.

• Targeting NCT market launch in first half of 2027.

• Continued pursuit of non-dilutive funding, strategic partnerships, and licensing opportunities.